中国房颤介入治疗现状与医疗质量分析
该调查覆盖全国7大区域17家区域医学中心,随机抽查2017年房颤导管消融和左心耳封堵病历。结果显示介入治疗总体规范安全,消融并发症低、术后抗凝率高,但CHA2DS2-VASc评分记录率低且各中心指标差异大。
要点
- 房颤导管消融术后抗凝率98.6%,16/17中心高于90%。
- 左心耳封堵适应证符合率81.3%,手术量≥20例中心更高。
- 仅15.8%非瓣膜性房颤病历记录CHA2DS2-VASc评分。
核心结论
- 我国房颤介入治疗总体规范且安全,并发症发生率较低,消融术后抗凝比例高,左心耳封堵适应证符合率尚可,但上述指标在不同中心差异大。
研究设计与样本
- 在全国7大区域各选1~3家区域医学中心,随机抽取2017年全年房颤导管消融及左心耳封堵住院病历进行分析。
- 17家中心2017年共行房颤导管消融术10 800例、左心耳封堵术447例;抽取导管消融病历1 347份和左心耳封堵病历160份。
- 10/17中心房颤导管消融手术量<500例,7/17中心左心耳封堵手术量<20例。
主要发现
- 15.8%(238/1 505)的非瓣膜性房颤患者病历中记录了CHA2DS2-VASc评分。
- 房颤导管消融术后抗凝率为98.6%(1 328/1 347),16/17的中心抗凝率高于90%。
- 导管消融术的并发症和严重并发症发生率分别为0.9%(12/1 347)和0.4%(5/1 347)。
- 左心耳封堵适应证符合率为81.3%(130/160),手术量≥20例的中心符合率高于<20例的中心[84.8%(106/125)比68.6%(24/35),P<0.05]。
- 左心耳封堵术的并发症和严重并发症发生率分别为3.1%(5/160)和1.9%(3/160);手术量<20例的中心并发症发生率高于≥20例的中心[8.6%(3/35)比1.6%(2/125),P<0.05]。
临床怎么用
- 应提高非瓣膜性房颤患者CHA2DS2-VASc评分的病历记录率以规范抗凝决策。
- 导管消融术后高抗凝率值得保持,但需关注各中心间差异。
- 左心耳封堵应严格把握适应证,手术量<20例的中心并发症发生率更高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To define the current status and analyze the medical quality of interventional therapy for patients with atrial fibrillation (AF) in China. Methods: This survey was performed in all seven large regions of China, one to three regional major medical centers were selected from each region. Medical records of patients underwent interventional therapy for AF in the year 2017 were randomly inspected. CHA2DS2-VASc score, prescribed anticoagulant after ablation, indication of left atrial appendage occlusion (LAAO), and complications in the medical records were analyzed. Results: A total of 10 800 AF catheter ablations and 447 LAAOs were performed in 17 regional medical centers in 2017. There were 10/17 centers performing AF catheter ablation<500 cases and 7/17 centers performing LAAO<20 cases. A total of 1 347 cases of catheter ablation and 160 cases of LAAO were selected for further analysis. Among all selected cases, 15.8% (238/1 505) non-valvar AF cases recorded CHA2DS2-VASc scores. The anticoagulation rate after AF catheter ablation was 98.6% (1 328/1 347), anticoagulation rate was higher than 90% in 16 out of 17 centers. The complication and severe complication rates of AF catheter ablation were 0.9% (12/1 347) and 0.4% (5/1 347), respectively. The differences of complication and severe complication rates in AF catheter ablation were similar between centers performing<500 cases and centers performing ≥500 cases (0.5% (2/413) vs. 1.1% (10/934), P>0.05; 0.5% (2/413) vs. 0.3% (3/934), P>0.05). The coincidence rate of LAAO indication was 81.3% (130/160), and the rate was higher in center performing ≥20 cases than in centers performing<20 cases (84.8% (106/125) vs. 68.6% (24/35), P<0.05). The complication and severe complication rates of LAAO were 3.1% (5/160) and 1.9% (3/160). The rate of complications in LAAO was higher in center performing<20 cases than in centers performing ≥20 cases (8.6% (3/35) vs. 1.6% (2/125), P<0.05), and there was no significant difference in severe complication rate (5.7% (2/35) vs. 0.8% (1/125), P>0.05). Conclusions: Interventional therapy for AF in China is generally standardized and safe. The overall incidence of complications post AF interventional ablation is low, the anticoagulation rate after AF catheter ablation is high, and the adherence rate of LAAO indication is fair. The indicators mentioned above vary widely among centers. 目的: 描述我国心房颤动(房颤)介入治疗的现况并对医疗质量开展分析。 方法: 在全国7大区域中分别选取1~3家区域医学中心,按比例随机抽取各中心2017年全年行房颤介入治疗(导管消融术及左心耳封堵术)的住院病历,收集CHA2DS2-VASc评分记录、导管消融术后抗凝、是否符合左心耳封堵术适应证等情况,并分析当次住院期间介入治疗相关并发症和严重并发症。 结果: 17家中心2017年共行房颤导管消融术10 800例、左心耳封堵术447例。10/17中心房颤导管消融手术量<500例,7/17中心左心耳封堵手术量<20例。共抽取行导管消融术和左心耳封堵术病历1 347和160份。15.8%(238/1 505)的非瓣膜性房颤患者病历中记录了CHA2DS2-VASc评分。房颤导管消融术后抗凝率为98.6%(1 328/1 347),16/17的中心抗凝率高于90%;导管消融术的并发症和严重并发症发生率分别为0.9%(12/1 347)和0.4%(5/1 347);导管消融手术量<500例的中心并发症以及严重并发症发生率与手术量≥500例的中心差异无统计学意义[0.5%(2/413)比1.1%(10/934),P>0.05;0.5%(2/413)比0.3%(3/934),P>0.05]。左心耳封堵适应证符合率为81.3%(130/160),其中手术量≥20例的中心符合率高于手术量<20例的中心[84.8%(106/125)比68.6%(24/35),P<0.05];左心耳封堵术的并发症和严重并发症发生率分别为3.1%(5/160)和1.9%(3/160),左心耳封堵手术量<20例的中心并发症发生率高于手术量≥20例的中心[8.6%(3/35)比1.6%(2/125),P<0.05],严重并发症发生率差异无统计学意义[5.7%(2/35)比0.8%(1/125),P>0.05]。 结论: 我国房颤介入治疗总体规范且安全,并发症总体发生率较低、导管消融术后抗凝比例高、左心耳封堵术适应证符合率总体尚可,但上述指标在不同中心差异大。.
引用
- Hu ZC, Jiang C, Liu SY, et al. [Current status and quality analysis of interventional therapy for patients with atrial fibrillation in China]. Zhonghua Xin Xue Guan Bing Za Zhi. 2021. PMID: 33706455. doi:10.3760/cma.j.cn112148-20201123-00929
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。